Legislation drafted by Sen. Kay
Hagan (D-N.C.) in collaboration with BIO seeks to create an FDA progressive
approval pathway that could expand accelerated approval to include virtually
all new molecular entities.
The Transforming the Regulatory
Environment to Accelerate Access to Treatments (TREAT) Act also would give FDA
authority to approve compounds based on approvals in Europe and some other
countries.